Results 171 to 180 of about 765,059 (313)

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Structural and functional insights into internal domain replacement in SpCas9 for protein engineering. [PDF]

Sci Rep
Kim S, Won H, Bae J, Kim J, Choi J, Richar H, Kim YG, Choi HJ.   +7 more
europepmc   +1 more source

Protein engineering in haemoglobin [PDF]

Nature, 1992
Giardina, B, Scatena, R, Clementi, M, Cerroni, L, CONDO', SAVERIO GIOVANNI, Nuutinen, M, Brix, O.   +6 more
openaire   +4 more sources

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Biophysics-based protein language models for protein engineering. [PDF]

Nat Methods
Gelman S, Johnson B, Freschlin CR, Sharma A, D'Costa S, Peters J, Gitter A, Romero PA.   +7 more
europepmc   +1 more source

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

Molecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens, Anouk Mentink, Tom Niessink, Frank Coumans, Leonie Mekenkamp, Ruchi Bansal, Jeroen Hiltermann   +6 more
wiley   +1 more source

Combinatorial protein engineering identifies potent CRISPR activators with reduced toxicity. [PDF]

Nat Commun
Giddins M, Kratz AF, De Los Santos MB, Forget A, Tiwari R, Jang G, Blazejewski T, Qin C, Huang Y, Lao YH, Falconer T, Leong KW, Krogan N, Staller M, Wang H, Wei L, Chavez A.   +16 more
europepmc   +1 more source

Protein engineering: The power of four.

Nature chemistry, 2015
Arnold J. Boersma, Gerard Roelfes
openaire   +2 more sources

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

Enzyme Engineering Database (EnzEngDB): a platform for sharing and interpreting sequence-function relationships across protein engineering campaigns. [PDF]

Nucleic Acids Res
Long Y, Abbasinejad F, Li FZ, Reinprecht P, Wittmann B, Kennemur JL, Carder H, Yang J, Lambert T, O'Meara R, Radtke L, Qin Z, Brinkmann-Chen S, Arnold F, Mora A.   +14 more
europepmc   +1 more source